Filing Flows › Comparisons › AXSM vs ZYME
Axsome Therapeutics vs Zymeworks: AXSM and ZYME compared
Axsome Therapeutics is the larger company: $260M of revenue in its latest quarter (Q3 2026) against $256M for Zymeworks (Q3 2026). Zymeworks is growing faster (+829% against +52% a year earlier). Zymeworks is more profitable, with an operating margin of 69.2% against -4.3%.
Where the money goes: AXSM and ZYME
Axsome Therapeutics (AXSM) · Q3 2026
Axsome Therapeutics, Q3 2026: revenue $260M (+52% year over year), operating margin -4.3%, net loss $12.9M, operating cash flow −$9.5M. The chart follows the revenue to costs, profit and cash.
Zymeworks (ZYME) · Q3 2026
Zymeworks, Q3 2026: revenue $256M (+829% year over year), operating margin 69.2%, net earnings $174M, operating cash flow −$24.0M. The chart follows the revenue to costs, profit and cash.
| Axsome Therapeutics (AXSM) | Zymeworks (ZYME) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $260M | $256M |
| Revenue growth, Y/Y | +52% | +829% |
| Operating margin | -4.3% | 69.2% |
| Net earnings | −$12.9M | $174M |
| Net margin | -5.0% | 67.7% |
| Operating cash flow | −$9.5M | −$24.0M |
| Market value | $8.8B | $1.9B |
| Analysts’ mean target | $265.86 | $41.50 |
Where the revenue comes from
Axsome Therapeutics
- Product: $250M (96%)
- Royalty and Milestone Revenue: $9.7M (4%)
Zymeworks
- License and milestone revenue: $250M (97%)
- Royalty and other revenue: $4.9M (2%)
- Viatris collaboration agreement revenue: $1.5M (1%)
Questions
Which is bigger, Axsome Therapeutics or Zymeworks?
Axsome Therapeutics is the larger company: $260M of revenue in its latest quarter (Q3 2026) against $256M for Zymeworks (Q3 2026).
Is Axsome Therapeutics or Zymeworks growing faster?
Zymeworks is growing faster (+829% against +52% a year earlier).
Which is more profitable, Axsome Therapeutics or Zymeworks?
Zymeworks is more profitable, with an operating margin of 69.2% against -4.3%.
More: Axsome Therapeutics earnings · how Axsome Therapeutics makes money · Zymeworks earnings · how Zymeworks makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.